NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

NCT04682587

CompletedN/A

Sponsor: Pfizer

Conditions: Renal Cell Carcinoma

Interventions: Axitinib, Avelumab, Pembrolizumab

Countries: United States

To assess how dose reductions or treatment interruptions related to axitinib can be implemented to manage and resolve adverse events occurring among patients with advanced renal cell carcinoma treated with first-line axitinib in combination with avelumab or pembrolizumab

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

Physicians meeting the following criteria will be invited to participate in the chart review study:

* Specialty in oncology
* Access to complete medical records for at least one patient with advanced RCC who meets the patient eligibility criteria

Eligible oncologists will be asked to select up to three patients meeting the following criteria for inclusion in the chart review study:

* Confirmed diagnosis with advanced RCC
* Treated with first-line axitinib/IO combination therapy at or after diagnosis
* Experienced at least one AE (i.e., diarrhea, fatigue, nausea, hypertension, and palmar-plantar erythrodysesthesia \[hand-foot syndrome\]) while treated with axitinib/IO combination therapy
* Age 18 years or older at the time of advanced RCC diagnosis
* Initiated axitinib/IO combination therapy at least 3 months prior to the start date of medical chart abstraction to ensure sufficient follow-up time

Exclusion Criteria:

There are no exclusion criteria for this study

Locations (1)

New York, New York, United States